logo

Heron Therapeutics Inc. (HRTX)



Trade HRTX now with
  Date
  Headline
3/2/2020 7:33:20 AM Heron Therapeutics Q4 Loss Per Share $0.65 Vs Loss $0.63 Last Year
1/13/2020 8:37:18 AM Heron Therapeutics Q4 Net Product Sales For CINV Franchise Of $34.8 Mln, Up 21% Y-o-Y
12/3/2019 7:34:13 AM Health Canada Grants Priority Review Status For Heron' NDS For HTX-011 For Management Of Postoperative
10/28/2019 8:36:03 AM Heron : FDA Accepts NDA Resubmission For HTX-011 For Management Of Postoperative Pain
10/22/2019 8:34:47 AM Heron Announces FDA Approval Of SNDA To Expand CINVANTI Label For Single-Dose Regimen
10/4/2019 12:03:19 AM Heron Therapeutics Announces Pricing Of Public Offering Of 8.57 Mln Shares At $17.50/Shr
10/3/2019 4:07:20 PM Heron Therapeutics Announces Proposed Public Offering Of Common Stock
10/2/2019 7:49:08 AM Heron Reports Positive Topline Results From Phase 3b Clinical Study Of HTX-011 In Total Knee Arthroplasty
10/1/2019 4:12:56 PM Heron Therapeutics Appoints Stephen Davis To Board Of Directors
10/1/2019 8:32:58 AM Heron Resubmits New Drug Application To FDA For HTX-011 For Management Of Postoperative Pain
8/20/2019 8:32:05 AM Heron Therapeutics Announces Publication Of Results From EPOCH 2; Meets End Points
8/5/2019 8:57:33 AM  Heron Therapeutics Q2 Loss/shr $0.63 Vs. Loss/shr $0.54 Prior Year
5/21/2019 9:15:13 AM Heron Reports Publication Of Results From Phase 3 EPOCH 1 Study Of HTX-011 In Patients Undergoing Bunionectomy
5/9/2019 8:35:39 AM Heron Therapeutics Q1 Net Loss $63.0 Mln Or $0.80/Shr Vs Loss $52.3 Mln Or $0.81/Shr Last Year
  
 
>